Recombinant human growth hormone (GH) is commonly used to treat short stature in children. However， GH treatment has limited efficacy， particularly in severe， non-GH-deficient conditions such as chondrodysplasias， and potential off-target effects. Because short stature results from decreased growth plate chondrogenesis， we developed a cartilage-targeting single-chain human antibody fragment (CaAb) aiming to deliver therapeutic molecules to the growth plate， thereby increasing treatment efficacy while minimizing adverse effects on other tissues. To this end， we created fusion proteins of these CaAbs conjugated with insulin-like growth factor 1 (IGF-1)， an endocrine and/or paracrine factor that positively regulates chondrogenesis. These CaAb-IGF-1 fusion proteins retained both cartilage binding and IGF-1 biological activity， and they were able to stimulate bone growth in an organ culture system. Using a GH-deficient (lit) mouse model， we found that subcutaneous injections of these CaAb-IGF-1 fusion proteins increased overall growth plate height without increasing proliferation in kidney cortical cells， suggesting on-target efficacy at the growth plate and less off-target effect on the kidney than IGF-1 alone. Alternate-day injections of these fusion proteins， unlike IGF-1 alone， were sufficient to produce a therapeutic effect. Our findings provide proof of principle that targeting therapeutics to growth plate cartilage can potentially improve treatment for childhood growth disorders.